Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5032356 | 0.87 | SCNN1A (0.60) | SCNN1A | |
| Hydrochloric Acid SCHEMBL5031394 | 0.86 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL5029299 | 0.83 | SCNN1A (0.36) | SCNN1A | |
| Hydrochloric Acid SCHEMBL5036392 | 0.81 | SCNN1A (0.52) | SCNN1A | |
| SCHEMBL5029498 | 0.77 | SCNN1A (0.31) | SCNN1A | |
| SCHEMBL938374 | 0.72 | SCNN1A (0.75) | SCNN1A | |
| 552-02 Free Base SCHEMBL2015164 | 0.71 | SCNN1A (1.00) | SCNN1A | |
| SCHEMBL3524561 | 0.70 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL14189645 | 0.70 | SCNN1A (0.41) | SCNN1A | |
| SCHEMBL14189634 | 0.69 | SCNN1A (0.40) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7317013-B2 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103148-A1 | CYCLIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, KCNH2, CACNA1B | SCNN1A 36/4885 |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | SCNN1A 14/4885 |
| US-20050059676-A1 | Cyclic pyrazinoylguanidine sodium channel blockers | HCN4, KCNH2, CACNA1B | SCNN1A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.